# A Trial of Centanafadine Efficacy, Safety, and Tolerability in Adult Subjects With Binge Eating Disorder

> **NCT05113953** · PHASE2 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 147 (actual)

## Conditions studied

- Binge-Eating Disorder

## Interventions

- **DRUG:** Centanafadine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05113953
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-22
- **Primary completion:** 2022-08-19
- **Final completion:** 2022-08-19
- **Target enrollment:** 147 (ACTUAL)
- **Last updated:** 2025-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05113953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05113953, "A Trial of Centanafadine Efficacy, Safety, and Tolerability in Adult Subjects With Binge Eating Disorder". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05113953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*